Core Viewpoint - Beijing Puxi Pharmaceutical Technology Co., Ltd. (Puxi Pharma) has submitted its listing application on the Hong Kong Stock Exchange, aiming for a valuation of approximately 2.4 billion RMB, despite currently having no approved products and facing significant financial losses [1][2]. Company Overview - Puxi Pharma focuses on the field of immune inflammation, positioning itself as a leader in localized delivery targeted therapies. The company was established in 2016 and has developed a core technology platform centered on innovative design and localized delivery [1][2]. - The company has not generated any product sales revenue, reporting net losses of approximately 178 million RMB and 125 million RMB for the fiscal years 2024 and the first nine months of 2025, respectively [1][2]. Product Pipeline - Puxi Pharma's core product, PG-011 (Pumexitinib), is a JAK1/JAK2 inhibitor designed for external use, with formulations including gel and nasal spray currently in late-stage clinical trials [2][3]. - The Pumexitinib gel is the first JAK inhibitor gel globally for treating atopic dermatitis, having completed Phase III trials for adults and adolescents aged 12 to 17, with plans to expand indications to children aged 2 to 11 [2][3]. - The nasal spray formulation is the first clinical-stage JAK inhibitor for treating seasonal allergic rhinitis (SAR) and is currently in Phase III trials for adults [3]. Market Potential - The global autoimmune disease drug market is projected to grow from $116.9 billion in 2019 to $143.1 billion by 2024, with a compound annual growth rate (CAGR) of 4.1%. The market is expected to reach $179.5 billion and $217 billion by 2028 and 2033, respectively [4][5]. - In China, the autoimmune disease drug market is anticipated to expand from 16.2 billion RMB in 2019 to 32.8 billion RMB by 2024, with a CAGR of 15.1% [5]. Competitive Landscape - The JAK inhibitor market is highly competitive, with three oral JAK1 inhibitors already approved in China for treating moderate to severe atopic dermatitis, alongside 19 other candidates in clinical stages [5][6]. - Puxi Pharma faces challenges as a latecomer in a crowded market, needing to establish differentiation in efficacy, safety, or compliance to succeed [5][6]. Commercialization Strategy - Puxi Pharma has signed an exclusive commercialization agreement with a subsidiary of Jichuan Pharmaceutical, granting them rights to commercialize the Pumexitinib nasal spray in China, with a potential payment of up to 100 million RMB [7]. - The company’s reliance on the core product for valuation and cash flow is significant, as other pipeline candidates are still in early development stages [7].

Core Viewpoint - Beijing Puxi Pharmaceutical Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange after withdrawing its IPO application from the Beijing Stock Exchange, reflecting a strategic shift for unprofitable biotech companies in the current market environment [1][3][6] Company Overview - Puxi Pharmaceutical, established in 2016, focuses on the field of immune inflammation, with its core product being Pumeixin (PG-011) [3][6] - The company has not yet launched any products, with its core product currently in various stages of clinical trials [1][3] Financial Performance - The company reported a cumulative loss exceeding 300 million yuan from 2024 to the first three quarters of 2025, with a net loss of 178.496 million yuan for 2024 and 125 million yuan for the first three quarters of 2025 [2][6] - Puxi Pharmaceutical's revenue was zero for 2022 and 2023, with only 47,200 yuan in revenue from other business activities in 2024 [5][6] Strategic Shift - The decision to switch from the Beijing Stock Exchange to the Hong Kong Stock Exchange is seen as a pragmatic adjustment due to the more stringent review process for unprofitable companies on the former [1][6] - The Hong Kong Stock Exchange's Chapter 18A is designed for unprofitable biotech companies, offering lower listing thresholds and faster access to capital [1][6] Product Development - Pumeixin has two formulations: a gel for atopic dermatitis and a nasal spray for allergic rhinitis, both of which are in advanced clinical trial stages [7][8] - The gel has completed Phase III trials for adults and adolescents, while the nasal spray is in Phase III trials for adults [7] Commercial Collaboration - Puxi Pharmaceutical has signed an exclusive commercialization agreement with Jichuan Pharmaceutical, allowing the latter to market Pumeixin nasal spray in China for up to 1 billion yuan [8][9] - This partnership is expected to provide essential funding and leverage Jichuan's commercial expertise to expedite market entry for Puxi's products [9]